MaTAR25: a long non-coding RNA involved in breast cancer progression.

IF 2.6 Q3 ONCOLOGY

Molecular and Cellular Oncology Pub Date : 2021-02-22 eCollection Date: 2021-01-01 DOI:10.1080/23723556.2021.1882286

Kung-Chi Chang, David L Spector

引用次数: 0

Abstract

We recently reported on the role of Mammary Tumor Associated RNA 25 (MaTAR25) in mammary tumor cell proliferation, migration, and invasion. MaTAR25 interacts with transcriptional activator protein Pur-beta (Purb) to regulate its downstream targets such as Tensin1 in trans. The human ortholog of MaTAR25, LINC01271, is upregulated with human breast cancer stage and metastasis.

查看原文本刊更多论文

MaTAR25:参与乳腺癌进展的长链非编码RNA

我们最近报道了乳腺肿瘤相关RNA 25 (MaTAR25)在乳腺肿瘤细胞增殖、迁移和侵袭中的作用。MaTAR25与转录激活蛋白pur - β (Purb)相互作用，调节其下游靶标，如反式中的Tensin1。MaTAR25的人类同源基因LINC01271随着人类乳腺癌分期和转移而上调。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular and Cellular Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

3.20

自引率

0.00%

发文量

期刊介绍： For a long time, solid neoplasms have been viewed as relatively homogeneous entities composed for the most part of malignant cells. It is now clear that tumors are highly heterogeneous structures that evolve in the context of intimate interactions between cancer cells and endothelial, stromal as well as immune cells. During the past few years, experimental and clinical oncologists have witnessed several conceptual transitions of this type. Molecular and Cellular Oncology (MCO) emerges within this conceptual framework as a high-profile forum for the publication of fundamental, translational and clinical research on cancer. The scope of MCO is broad. Submissions dealing with all aspects of oncogenesis, tumor progression and response to therapy will be welcome, irrespective of whether they focus on solid or hematological neoplasms. MCO has gathered leading scientists with expertise in multiple areas of cancer research and other fields of investigation to constitute a large, interdisciplinary, Editorial Board that will ensure the quality of articles accepted for publication. MCO will publish Original Research Articles, Brief Reports, Reviews, Short Reviews, Commentaries, Author Views (auto-commentaries) and Meeting Reports dealing with all aspects of cancer research.